（文章来源：证券日报） 证券日报网讯 12月8日，乐心医疗在互动平台回答投资者提问时表示，公司拥有多维度体征健康监测产 品线，包括主营产品：智能电子血压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备 以及手环手表等，前述产品为公司主要收入来源；近年推出的产品OTC助听器和十二导联智能心电衣 （通过参股公司布局）正逐步实现商业落地（其未来对公司业绩的影响公司尚无法预判，请注意投资风 险）。公司的医疗级智能戒指目前在持续筹备优化中，尚未正式发布，该产品相对现有手表手环从功能 侧而言，在血氧、睡眠、心率、运动等基本监测功能外，还提供心血管状态的监测与评估，从外形来说 更加便携精巧、佩戴舒适；（公司曾在2019年推出医疗级心电手表LifesenseHealthWatchH1，未曾发布 H2）。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 乐心医疗回复：尊敬的投资者您好！公司拥有多维度体征健康监测产品线，包括主营产品：智能电子血 压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备以及手环手表等，前述产品为公司 主要收入来源；近年推出的产品OTC助听器和十二导联智能心电衣（通过参股公司布局）正逐步实现商 业落地（其未来对公司业绩的影响公司尚无法预判，请注意投资风险）。公司的医疗级智能戒指目前在 持续筹备优化中，尚未正式发布，该产品相对现有手表手环从功能侧而言，在血氧、睡眠、心率、运动 等基本监测功能外，还提供心血管状态的监测与评估，从外形来说更加便携精巧、佩戴舒适；（公司曾 在2019年推出医疗级心电手表Lifesense Health Watch H1，未曾发布H2）；感谢您的关注，祝您投资顺 利，谢谢。 证券之星消息，乐心医疗(300562)12月08日在投资者关系平台上答复投资者关心的问题。 投资者提问：领导好，请问公司核心产品:十二导联智能心电衣（iSENSE系列）， Nova智听OTC助听 器，医疗级智 ...

Summary of Key Points Core Viewpoint The report outlines the management, storage, and usage of the funds raised by Guangdong Leshi Medical Electronics Co., Ltd. for the first half of 2025, detailing the total amount raised, the current balance, and the specific projects funded. Fundraising Overview - The company raised a total of RMB 385,356,068.13 by issuing 23,998,780 shares at a price of RMB 16.48 per share to 14 specific investors [1][2] - As of the end of 2024, the balance in the fundraising special account was RMB 190,328,551.27, with RMB 9,537,660.29 used in the current year, leaving a balance of RMB 182,230,103.57 as of June 30, 2025 [2][5] Fund Management - The company has established a fundraising management system to enhance the efficiency of fund usage, complying with relevant regulations [2][3] - Funds are stored in special accounts at various banks, including China Construction Bank and Bank of China, specifically for the purpose of managing the raised funds [3][4] Fund Usage - The actual usage of the raised funds for the first half of 2025 is detailed in an attached table, with no changes in project implementation locations or methods reported [7][8] - The company has approved the use of up to RMB 180 million of idle funds for cash management, investing in safe and liquid financial products [7][8] Project Adjustments - The company has decided to extend the timeline for certain projects, such as the "Smart Blood Glucose Monitoring Product Industrialization Project," to October 31, 2026, due to market conditions and operational needs [8][10] - The remaining RMB 5,627.60 million from the "TWS Earphone Production Line Construction Project" will be used for permanent working capital [10][12] Compliance and Reporting - The company confirms that there are no issues with the disclosure of fundraising usage, and all activities comply with regulatory requirements [8][9] - The report was approved by the board of directors on August 14, 2025 [8]

Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, fat measuring devices, ECG monitoring equipment, smart bands, and smart watches [2] - The company is recognized as a national high-tech enterprise and has established several research and development centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - The latest financial report indicates that for Q1 2025, the company achieved operating revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, a year-on-year increase of 67.88%, with a gross sales margin of 37.38% [2] Group 2 - As of August 13, the company's stock closed at 17.11 yuan, with a rolling PE ratio of 52.85 times and a total market value of 3.733 billion yuan [1] - The average PE ratio in the medical device industry is 57.48 times, with a median of 40.95 times, placing the company at the 87th position in the industry ranking [1][3] - On August 13, the company experienced a net outflow of 1.934 million yuan in principal funds, with a total outflow of 4.205 million yuan over the past five days [1]

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Leksin Medical, indicating a decline in stock price and a relatively high PE ratio compared to industry averages [1][2] - As of August 12, Leksin Medical's stock closed at 16.92 yuan, down 1.57%, with a rolling PE ratio of 52.26 times and a total market capitalization of 3.692 billion yuan [1] - The average PE ratio for the medical device industry is 57.51 times, with a median of 41.25 times, placing Leksin Medical at the 86th position in the industry ranking [1][3] Group 2 - Leksin Medical specializes in health IoT and digital health services, with key products including smart electronic blood pressure monitors, electronic health scales, and smart glucose monitoring devices [2] - The company is recognized as a national high-tech enterprise and has established several engineering technology research centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - In the latest quarterly report for Q1 2025, Leksin Medical reported revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, reflecting a year-on-year growth of 67.88% with a gross profit margin of 37.38% [2]

Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Leksin Medical, indicating a recent increase in stock price and a low rolling PE ratio compared to the industry average [1] - As of August 7, Leksin Medical's stock closed at 16.8 yuan, with a PE ratio of 51.89, marking a new low in 106 days, and a total market capitalization of 3.666 billion yuan [1] - The medical device industry has an average PE ratio of 54.79, with Leksin Medical ranking 87th among its peers [1] Group 2 - Leksin Medical specializes in health IoT and digital health services, producing various smart health monitoring devices [2] - The company has achieved multiple quality certifications, including ISO13485:2016 and ISO9001:2015, and its products have received international certifications such as FDA and CE [2] - In the first quarter of 2025, Leksin Medical reported a revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, reflecting a significant year-on-year growth of 67.88% [2] Group 3 - The PE ratios of Leksin Medical are compared to other companies in the industry, with its TTM PE at 51.89 and static PE at 59.74, alongside a price-to-book ratio of 3.59 [3] - The industry average PE is 54.79, while the median is 37.86, indicating Leksin Medical's valuation is above the median but below the average [3] - The total market capitalization of Leksin Medical is reported at 3.666 billion yuan, positioning it within the competitive landscape of the medical device sector [3]

Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, body fat measurement devices, ECG monitoring equipment, smart bands, and smart watches [2] - The company is recognized as a national high-tech enterprise and has established several engineering technology research centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - The company has achieved various international certifications, including ISO13485:2016 for medical device quality management, and its products have received FDA registration in the US, CE certification in the EU, and other international certifications [2] Group 2 - As of August 1, the company's stock closed at 16.46 yuan, with a rolling PE ratio of 50.67 times and a total market value of 3.579 billion yuan [1] - The average PE ratio in the medical device industry is 53.65 times, with a median of 37.22 times, placing the company at the 87th position in the industry ranking [1][3] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, a year-on-year increase of 67.88%, with a gross profit margin of 37.38% [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of 乐心医疗 (Loxin Medical), indicating a recent stock price increase and a relatively low PE ratio compared to the industry average [1][2]. - As of July 28, 乐心医疗's stock closed at 16.5 yuan, with a PE ratio of 50.80, marking a new low in 98 days, and a total market capitalization of 3.588 billion yuan [1]. - The average PE ratio for the medical device industry is 55.28, with a median of 38.06, positioning 乐心医疗 at 86th place within the industry [1][3]. Group 2 - 乐心医疗 specializes in health IoT and digital health services, offering products such as smart electronic blood pressure monitors, electronic health scales, and smart glucose monitoring devices [2]. - The company is recognized as a national high-tech enterprise and has established several engineering technology research centers, focusing on the R&D, production, and sales of home medical health electronic products [2]. - In the first quarter of 2025, 乐心医疗 reported a revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, reflecting a significant year-on-year growth of 67.88% [2].

Company Overview - LeXin Medical focuses on health IoT and digital health services, offering products such as smart electronic blood pressure monitors, health scales, blood glucose monitoring devices, fat measuring instruments, ECG monitoring equipment, smart bands, and smartwatches [2] - The company is recognized as a national high-tech enterprise and has established several research and development centers, including the Guangdong Provincial Engineering Technology Research Center [2] - LeXin Medical has obtained various international certifications, including ISO13485:2016, ISO9001:2015, ISO14001:2015, FDA registration, CE certification, and others, indicating its commitment to quality and international standards [2] Financial Performance - In the first quarter of 2025, LeXin Medical reported revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, up 67.88% year-on-year, with a gross profit margin of 37.38% [2] - As of July 9, 2023, the company's stock closed at 15.85 yuan, with a rolling PE ratio of 48.79, marking a new low in 65 days, and a total market capitalization of 3.447 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing LeXin Medical at the 87th position within the industry [1][3] - The company's current PE ratio is lower than the industry average, indicating potential valuation opportunities [1][3]

Group 1 - The core viewpoint of the news highlights the performance and market position of Leksin Medical, indicating a decline in stock price and a relatively high PE ratio compared to industry averages [1][2] - As of June 18, Leksin Medical's stock closed at 14.19 yuan, down 1.60%, with a rolling PE ratio of 43.68 times and a total market capitalization of 3.086 billion yuan [1] - In the medical device industry, the average PE ratio is 49.10 times, while the median is 36.43 times, placing Leksin Medical at the 87th position in the industry ranking [1][3] Group 2 - Leksin Medical specializes in health IoT and digital health services, with key products including smart electronic blood pressure monitors, health scales, blood glucose monitoring devices, and ECG monitoring equipment [2] - The company is recognized as a national high-tech enterprise and has established several engineering technology research centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - In the latest quarterly report for Q1 2025, Leksin Medical achieved a revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, up 67.88%, with a gross profit margin of 37.38% [2]